Aspire Biopharma Holdings (ASBP) Net Equity Issued and Repurchased (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Net Equity Issued and Repurchased of $9.0 million for Q1 2026, up 31240.36% quarter-over-quarter from $28561.0 in Q2 2024.
Aspire Biopharma Holdings (ASBP) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $9.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (changed N/A YoY), while the FY2024 annual figure was $2.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $9.0 million in Q1 2026 per ASBP's latest filing, from $28561.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $9.0 million in Q1 2026 and bottomed at $28561.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.00 Mn |
| Jun 30, 2026 | 9.00 Mn |
| Mar 31, 2026 | 8.95 Mn |
| Mar 31, 2026 | 8.95 Mn |
| Jun 30, 2024 | 28,561.00 |
| Jun 30, 2024 | 28,561.00 |
| Mar 31, 2024 | 229,084.00 |
| Mar 31, 2024 | 229,084.00 |